Urothelial Cancer | Specialty

The OncFive: Top Oncology Articles for the Week of 5/4

May 10th 2025

A doublet is approved for KRAS-mutated ovarian cancer, T-DXd followed by THP improves pCR rates in HER2+ breast cancer, and more from OncLive.

Durvalumab Plus BCG Improves DFS in High-Risk Non–Muscle-Invasive Bladder Cancer

May 9th 2025

Durvalumab plus BCG induction and maintenance improved DFS vs BCG in these settings alone in patients with high-risk non–muscle-invasive bladder cancer.

Dr Grivas on Incorporating Perioperative Durvalumab Plus Neoadjuvant Chemo into MIBC Management

May 7th 2025

Petros Grivas, MD, PhD, details questions and considerations for integrating perioperative durvalumab plus neoadjuvant chemotherapy into MIBC management.

Contrasting Adjuvant and Perioperative Trial Designs Help Refine MIBC Management

May 7th 2025

Petros Grivas, MD, PhD, discusses data from CheckMate 274 and how emerging data from bladder cancer trials are shaping immunotherapy strategies in MIBC.

Dr Schmidt on FDA-Approved Bladder-Sparing Therapies in BCG-Refractory NMIBC

May 6th 2025

Bogdana Schmidt, MD, MPH, highlights FDA approved bladder-sparing therapies for patients with BCG-refractory non–muscle-invasive bladder cancer.

NIAGARA Trial Validates Perioperative Durvalumab Approach in MIBC

May 6th 2025

Petros Grivas, MD, PhD, discusses key findings from the NIAGARA trial and how these data support the use of perioperative durvalumab in MIBC management.

FDA Issues Refusal to File Letter for Nogapendekin Alfa Inbakicept sBLA in BCG-Unresponsive Papillary NMIBC

May 5th 2025

A meeting has been requested to address the FDA's refusal to file an sBLA for nogapendekin alfa inbakicept plus BCG in BCG-unresponsive papillary NMIBC.

Five Under 5: Top Oncology Videos for the Week of 4/27

May 4th 2025

The top 5 OncLive videos of the week cover insights in colorectal cancer, prostate cancer, myeloma, renal cell carcinoma, and urothelial carcinoma.

Real-World Data Support Nadofaragene Firadenovec Use in BCG-Unresponsive NMIBC: With Jacob Moyer, BS; and Mark D. Tyson, II, MD, MPH

May 1st 2025

Oncology Experts Highlight the Key Data and Top Abstracts From AUA 2025

May 1st 2025

Experts revisit the most intriguing abstracts and data they saw presented at the 2025 American Urological Association Annual Meeting.

Subgroup Analysis Shows No Key Differences Between High-Grade Recurrence, Cancer Progression Outcomes in BCG-Unresponsive NMIBC

April 30th 2025

Among 3 subgroups of patients with BCG-unresponsive NMIBC, no significant clinical differences were identified regarding rates of high-grade recurrence.

Cancer Vaccines Begin to Take Center Stage With Investigators Anticipating an Even Brighter Future

April 30th 2025

Expert investigators discuss the current and future landscape of cancer vaccine development in various tumor types.

Padeliporfin VTP Therapy Yields Complete Responses With Manageable Safety in Low-Grade, Upper Tract Urothelial Cancer

April 29th 2025

Padeliporfin vascular targeted photodynamic therapy was safe and generated responses in low-grade, upper tract urothelial cancer.

Dr Guerrero-Ramos on the Potential Role of TAR-200 in BCG-Unresponsive Papillary NMIBC

April 29th 2025

Felix Guerrero-Ramos, MD, PhD, discusses the potential role of TAR-200 in high-risk, BCG-unresponsive, papillary-only non–muscle-invasive bladder cancer.

Dr Ghoreifi on the Feasibility for Consolidative Surgery After Enfortumab Vedotin/Pembrolizumab in Advanced Urothelial Cancer

April 28th 2025

Alireza Ghoreifi, MD, discusses the feasibility of consolidative surgery for advanced urothelial cancer receiving pembrolizumab/enfortumab vedotin.

TARA-002 Showcases Early Clinical Activity in BCG-Naive and -Unresponsive High-Risk NMIBC

April 27th 2025

Interim data from a phase 2 study support the potential of TARA-002 as an intravesical immunotherapy in high-risk NMIBC.

Neoadjuvant Mitomycin C Demonstrates Favorable Safety and Potential RFS Benefit in NMIBC

April 27th 2025

Neoadjuvant mitomycin C improved 18-month recurrence-free survival and demonstrated favorable safety in non–muscle-invasive bladder cancer.

Dr Jacob on the Potential for TAR-200 to Shift the Treatment Paradigm in NMIBC

April 27th 2025

Joseph Jacob, MD, MCR, discusses how emerging data for TAR-200 could represent a shift in the treatment paradigm for patients with high-risk non–muscle-invasive bladder cancer.

Dr Dinney on the Association Between UGDB and Cretostimogene Grenadenorepvec Response in NMIBC

April 27th 2025

Colin P.N. Dinney, MD, discusses urinary genomic disease burden as a potential biomarker for response to cretostimogene grenadenorepvec in bladder cancer.

Disitamab Vedotin/BCG Could Provide a New Bladder Sparing Therapy in HER2-Expressing High-Risk NMIBC

April 27th 2025

The addition of disitamab vedotin to BCG demonstrated high CR rates in HER2-expressing, high-risk NMIBC.